EMA Refused: Alsitek (Masitinib mesilate) — AB Science

View source ↗

Summary

The EMA refused approval for Masitinib mesilate (Alsitek) for amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Alsitek (Masitinib mesilate)

Snippet

Status: Refused. Therapeutic area: Amyotrophic Lateral Sclerosis. MAH: AB Science. Decision date: 20/04/2018. Orphan medicine